| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/LEU.2014.13 |
| P698 | PubMed publication ID | 24480973 |
| P50 | author | Brian A. Walker | Q40421006 |
| Christopher P Wardell | Q56422135 | ||
| Michele Cavo | Q57233657 | ||
| Gareth J. Morgan | Q61996585 | ||
| Annamaria Brioli | Q64225506 | ||
| P2093 | author name string | D C Johnson | |
| M F Kaiser | |||
| F E Davies | |||
| A Murison | |||
| D B Begum | |||
| G Vijayaraghavan | |||
| S Hulkki Wilson | |||
| I Titley | |||
| L Melchor | |||
| N E Potter | |||
| R A Fryer | |||
| P2860 | cites work | Cancer as an evolutionary and ecological process | Q22122026 |
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Control of autophagic cell death by caspase-10 in multiple myeloma | Q24337539 | ||
| Intratumor heterogeneity: evolution through space and time | Q24598678 | ||
| Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide | Q24614147 | ||
| Initial genome sequencing and analysis of multiple myeloma | Q24629117 | ||
| Targeting the BRAF V600E mutation in multiple myeloma | Q27852220 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| The clonal evolution of tumor cell populations | Q28271546 | ||
| Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment | Q28486349 | ||
| Clonal evolution in cancer | Q29547696 | ||
| The life history of 21 breast cancers | Q29614642 | ||
| Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing | Q29614647 | ||
| The patterns and dynamics of genomic instability in metastatic pancreatic cancer | Q29618121 | ||
| Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes | Q33558078 | ||
| Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype | Q33604942 | ||
| Interferon regulatory factor 4 and 8 in B-cell development | Q33662650 | ||
| Minor clone provides a reservoir for relapse in multiple myeloma | Q34147170 | ||
| Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. | Q34210005 | ||
| A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma | Q34418880 | ||
| IRF4 mutations in chronic lymphocytic leukemia | Q35212381 | ||
| Temporal dissection of tumorigenesis in primary cancers | Q35275682 | ||
| A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. | Q35984702 | ||
| Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides | Q36141838 | ||
| Clonal competition with alternating dominance in multiple myeloma. | Q36141846 | ||
| Molecular pathogenesis of multiple myeloma and its premalignant precursor | Q36290238 | ||
| Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. | Q36673354 | ||
| IRF4 addiction in multiple myeloma | Q36891060 | ||
| Genome evolution during progression to breast cancer | Q36973612 | ||
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms | Q37564751 | ||
| The genetic architecture of multiple myeloma. | Q38001913 | ||
| Single-cell mutational profiling and clonal phylogeny in cancer | Q39093250 | ||
| Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression | Q39223818 | ||
| Taking qPCR to a higher level: Analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution | Q39915256 | ||
| Detection of high incidence of K-ras oncogenes during human colon tumorigenesis | Q41822747 | ||
| Cancer stem cells as 'units of selection'. | Q42108136 | ||
| Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. | Q44086949 | ||
| Genetic variegation of clonal architecture and propagating cells in leukaemia | Q44426152 | ||
| ROCK: a breast cancer functional genomics resource. | Q45023042 | ||
| Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. | Q53170046 | ||
| Clonal architecture of chronic myelomonocytic leukemias | Q57219718 | ||
| Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma | Q58455735 | ||
| A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value | Q61905667 | ||
| Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma | Q61905672 | ||
| Genomic abnormalities in monoclonal gammopathy of undetermined significance | Q74541364 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phylogenetics | Q171184 |
| P304 | page(s) | 1705-1715 | |
| P577 | publication date | 2014-01-13 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma | |
| P478 | volume | 28 |
| Q33671792 | A Strategy to Delay the Development of Cisplatin Resistance by Maintaining a Certain Amount of Cisplatin-Sensitive Cells |
| Q38622920 | A river model to map convergent cancer evolution and guide therapy in RCC. |
| Q36055752 | APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma |
| Q92965873 | Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis |
| Q57166498 | An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when |
| Q51417340 | An activating mutation of interferon regulatory factor 4 (IRF4) in adult T cell leukemia. |
| Q48115878 | An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. |
| Q50057730 | Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups |
| Q64931827 | Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. |
| Q57803767 | Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma |
| Q38947180 | Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease |
| Q100526119 | Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) |
| Q47776210 | Chimeric antigen receptor T-cell therapies for multiple myeloma |
| Q40109575 | Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow |
| Q35081172 | Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations |
| Q64244656 | Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance |
| Q93035486 | Computational enhancement of single-cell sequences for inferring tumor evolution |
| Q34508313 | Curing myeloma at last: defining criteria and providing the evidence |
| Q34556156 | Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. |
| Q26825186 | Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine |
| Q36544069 | Detection of recurrent cytogenetic aberrations in multiple myeloma: a comparison between MLPA and iFISH. |
| Q96022610 | Evolution and structure of clinically relevant gene fusions in multiple myeloma |
| Q47913337 | Evolutionary biology of high-risk multiple myeloma |
| Q89804560 | Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines |
| Q41177165 | From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation |
| Q93032105 | GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice |
| Q43847809 | Gene Expression Profiles in Myeloma: Ready for the Real World? |
| Q38970573 | Genomic Aberrations in Multiple Myeloma |
| Q34537571 | Genomic complexity of multiple myeloma and its clinical implications |
| Q92027921 | High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment |
| Q40492260 | Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. |
| Q38733973 | IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal |
| Q58792995 | Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma |
| Q91844274 | Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone |
| Q23909636 | Impact of recent innovations in the use of mass cytometry in support of drug development |
| Q92615039 | Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis |
| Q89998369 | Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma |
| Q41520220 | Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer |
| Q41810975 | Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland |
| Q89093055 | Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data |
| Q36306807 | Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). |
| Q52691505 | Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition? |
| Q38979865 | MGUS to myeloma: a mysterious gammopathy of underexplored significance |
| Q37402009 | Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. |
| Q89622450 | Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression |
| Q89565340 | Molecular basis of clonal evolution in multiple myeloma |
| Q41612115 | Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. |
| Q60921242 | Molecular signatures of multiple myeloma progression through single cell RNA-Seq |
| Q64097718 | Multiple myeloma immunoglobulin lambda translocations portend poor prognosis |
| Q38943973 | Mutational landscape reflects the biological continuum of plasma cell dyscrasias |
| Q38572771 | Myeloma Propagating Cells, Drug Resistance and Relapse |
| Q38615431 | Neutral tumor evolution in myeloma is associated with poor prognosis. |
| Q33431541 | OncoNEM: inferring tumor evolution from single-cell sequencing data |
| Q38640514 | Oral ixazomib maintenance therapy in multiple myeloma. |
| Q27316833 | Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. |
| Q38671390 | Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. |
| Q38686915 | Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients |
| Q60203335 | Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential |
| Q36020424 | RNA-Seq following PCR-based sorting reveals rare cell transcriptional signatures |
| Q33417335 | Recurrent CDC25C mutations drive malignant transformation in FPD/AML. |
| Q92659402 | Resolving genetic heterogeneity in cancer |
| Q35797736 | SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma. |
| Q39100317 | Safety issues and management of toxicities associated with new treatments for multiple myeloma. |
| Q90080640 | Second malignancies in multiple myeloma; emerging patterns and future directions |
| Q34673769 | Single-Cell Analysis in Cancer Genomics |
| Q35753835 | Single-Cell Genetic Analysis Using Automated Microfluidics to Resolve Somatic Mosaicism |
| Q93382206 | Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia |
| Q38808490 | Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. |
| Q54963328 | Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. |
| Q90351167 | Spectrum and functional validation of PSMB5 mutations in multiple myeloma |
| Q39410899 | Standardisation of minimal residual disease in multiple myeloma |
| Q57734034 | Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability |
| Q30410213 | SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization |
| Q88891955 | T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma |
| Q33714724 | TPL2 kinase regulates the inflammatory milieu of the myeloma niche |
| Q39560208 | Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. |
| Q38970585 | Targeting the Bone Marrow Microenvironment. |
| Q26801730 | The 3' to 5' Exoribonuclease DIS3: From Structure and Mechanisms to Biological Functions and Role in Human Disease |
| Q64103324 | The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma |
| Q37443338 | The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. |
| Q93047941 | The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma |
| Q33917164 | The future of autologous stem cell transplantation in myeloma |
| Q91229404 | The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies |
| Q38192044 | The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. |
| Q38927463 | The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma |
| Q28076070 | The myeloma stem cell concept, revisited: from phenomenology to operational terms |
| Q36813990 | The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma |
| Q37245131 | The role of the RAS pathway in iAMP21-ALL. |
| Q36045385 | The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. |
| Q26744341 | Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance |
| Q28544663 | Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma |
| Q38681814 | Utilizing next-generation sequencing in the management of multiple myeloma. |
| Q33814223 | Zebrafish as a model to assess cancer heterogeneity, progression and relapse |
| Q89255970 | [Detection of circulating plasma cells in multiple myeloma with extramedullary plasmacytoma] |
Search more.